secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001815776-25-000030
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LENZ Therapeutics Q1 net loss $14.6M; LNZ100 PDUFA on track for Aug 8, 2025
---------------------------------------------------------------------------

- Net loss $14.6M ($0.53 per share) vs $16.6M ($3.53) YoY; R&D down to $5.8M, SG&A up to $11.1M.
- Cash $194.1M at Mar 31, 2025; anticipated balance >$185M at PDUFA; runway to post-launch positive cash flow.
- NDA for LNZ100 (aceclidine eye drop for presbyopia) on track; FDA PDUFA target date Aug 8, 2025.
- US Customs rulings confirm LNZ100 US origin and duty free, eliminating tariff exposure.
- Pre-commercial hiring of 88 sales reps targeted by Jul 1, 2025; raised $16.3M net from April ATM block trade.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000181577625000030/0001815776-25-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000181577625000030/lenz-20250507.htm
  HTML page:      https://secwatch.observer/filing/0001815776-25-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer